ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Impax Laboratories, Inc." (IPXL) Report Updated: Aug 22, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"Impax Laboratories, Inc." (IPXL)

Rating: Strong Sell Volatility: Moderate
Total Grade: F Industry: Pharmaceuticals
Competitors: HSKA,JNJ,BPTH,SUPN

Stock Analysis

Rating: Monthly View

A
B
C
D
F
August September October November December January February March April May June July

Rating: Weekly View

This Week: F down downgrade
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Impax Laboratories, Inc."© quotemedia

Company Profile

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products. It operates in two segments, Global Pharmaceuticals Division and Impax Pharmaceuticals Division. The Global Pharmaceuticals Division provides generic pharmaceutical products through its global products sales channel directly to wholesalers, large retail drug chains, and others; generic prescription products through third-party pharmaceutical entities to alliance and collaboration agreements; generic pharmaceutical over-the-counter (OTC) and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies. The Impax Pharmaceutical Division focuses on the development and promotion through its specialty sales force of proprietary brand pharmaceutical products for the treatment of central nervous system disorders, including migraine, multiple sclerosis, Parkinsonís disease, and postherpetic neuralgia. The company markets and sells its products to drug wholesalers, warehousing chain drug stores, mass merchandisers, and mail-order pharmacies in the continental United States and the Commonwealth of Puerto Rico. Impax Laboratories, Inc. has a strategic alliance agreement with Teva Pharmaceuticals Curacao N.V to develop, manufacture, and distribute controlled release generic pharmaceutical products. The company was founded in 1993 and is headquartered in Hayward, California.